Magrolimab
Magrolimab fails to improve survival in leukemia, Gilead halts trial
Anika Sharma
Another failure has occurred in Gilead Sciences’ $4.9 billion immuno-oncology wager. Following an ad hoc analysis of a phase 3 ...
Gilead’s Magrolimab Faces Fresh Setback as FDA Issues Partial Clinical Hold
Anika Sharma
One month after Gilead Sciences made public its decision to halt a myelodysplastic syndromes (MDS) program centered around magrolimab, the ...
Magrolimab for myelodysplastic syndromes is discontinued by Gilead
SG Tylor
Source – Gilead Science Gilead Sciences has announced the discontinuation of its cancer antibody, magrolimab, in the treatment of blood ...
